As of November 7, 2026, Latigo Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 5, 2026 (Form 8-K, November 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Latigo Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Latigo Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-05. Every row below is cited to the filing it comes from, and this page adds each new change as Latigo Biotherapeutics, Inc. files it.
Also on the record for Latigo Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by AI Biotechnology LLC | 4.8% of the class | 5%+ stakes | Source |
| October 29, 2026 | Stake report, Schedule 13G, by Dr. Beth C. Seidenberg | 19.9% of the class | 5%+ stakes | Source |
| August 18, 2026 | Stake report, Schedule 13G, by AI Biotechnology LLC | 5% of the class | 5%+ stakes | Source |
| August 17, 2026 | Stake report, Schedule 13D, by Foresite Capital Fund VI LP | 14.5% of the class | 5%+ stakes | Source |
| August 17, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 8.4% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 7.03% of the class | 5%+ stakes | Source |
| August 7, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| August 4, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| August 3, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| July 17, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 13, 2025 | Form D, private offering | $50M sold | Form D page | Source |
Selling to them or working with them? See who runs Latigo Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Latigo Biotherapeutics, Inc. and the records around it.
Latigo Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Westlake BioPartners Fund I, L.P. also filed stake reports on 2 other companies: Electra Therapeutics, Inc. (Oct 2026), Kyverna Therapeutics, Inc. (Feb 2026)
- AI Biotechnology LLC also filed stake reports on 3 other companies: Yarrow Bioscience, Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026), Zura Bio Limited (Mar 2026)
- Foresite Capital Fund VI LP also filed stake reports on 4 other companies: IRulya Therapeutics Inc. (Oct 2026), Alumis Inc. (Aug 2026), Verastem, Inc. (May 2026)
Watch Latigo Biotherapeutics, Inc.
Get an email when Latigo Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Latigo Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Latigo Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Latigo Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | Reported | not named in the filing | 8-K, 2026-11-05 |
New leaders reset buying decisions — get the Full Report on Latigo Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Latigo Biotherapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Latigo Biotherapeutics, Inc.Every change, in the filing's words
Reported
On November 3, 2026 (the "Effective Date"), the Board of Directors (the "Board") of the Company approved the appointment of Todd Smith as the Company's President and Chief Executive Officer, replacing Nima Farzan in such capacities.
- The appointment of Mr. Smith to these positions became effective as of the Effective Date, at which point Mr. Farzan ceased to serve in these positions and resigned as a member of the Board.
- Mr. Farzan's resignation from the Board was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Company and Mr. Farzan entered into a transition and separation agreement, pursuant to which Mr. Farzan will continue as an employee of the Company through January 1, 2027, unless earlier terminated (such date on which Mr. Farzan's employment is terminated, the "Employment Separation Date" and the period between the Effective Date and the Employment Separation Date, the "Employment Transition Period").
- During the Employment Transition Period, Mr. Farzan will continue to receive his current compensation.
- Following the Employment Separation Date, Mr. Farzan has agreed to continue as a consultant, providing transitional and advisory services through December 31, 2027, unless earlier terminated (such period, the "Consulting Period").
- Mr. Farzan will continue to vest in his outstanding equity awards as the sole consideration for his consulting services during the Consulting Period.
Tools for this story
Each opens in a new tab, filled in for Latigo Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.